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Key Message 21 
Anti-Müllerian hormone (AMH) is lower in young women with renal failure compared with 22 
age-matched healthy controls but not in those on haemodialysis. AMH decreases with age in 23 
women with renal failure in a similar manner to the general population. AMH may have a 24 
role as a marker of ovarian health in non-dialysis renal patients pursuing pregnancy. 25 
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Abstract 26 
Women with renal disease have menstrual and gonadal dysfunction manifesting as hormonal 27 
imbalance. Anti-Müllerian hormone (AMH) has been described as a potential measure of the 28 
ovarian reserve. We examined circulating AMH levels in young women with renal failure 29 
divided into 3 groups, determined associations with clinical characteristics, and compared 30 
AMH with age-matched healthy individuals. AMH concentrations were measured in 77 31 
women (mean age 32.9±5.4 years); 26 had chronic kidney disease (CKD) stages 3-5, 26 were 32 
on haemodialysis (HD), and 25 had a kidney transplant. Random AMH levels are highest in 33 
women on HD [HD 2.9 (1.1-5.2), CKD 1.6 (0.7-2.2), transplant 1.5 (1.0-4.2)ng/mL]. On 34 
multiple linear regression, AMH was 53% higher (95% CI 0.20-0.98, p=0.002) in women on 35 
HD and decreased by 20% per 5-year increase in age (p<0.001). AMH was 43% lower in 36 
women with renal failure compared with 600 age-matched controls [1.7 (0.9-3.8) vs 3.0 (1.9-37 
5.0)ng/mL, p<0.001]; however, we found no difference in AMH between those on HD and 38 
healthy individuals [2.9 (1.1-5.2) vs 3.0 (1.9-5.0)ng/mL]. AMH may be a useful biomarker in 39 
female renal patients with non-dialysis dependent renal disease pursuing pregnancy. In 40 
contrast, AMH levels are higher in HD but unlikely to reflect ovarian reserve. 41 
 42 
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Introduction 51 
Anti-Müllerian hormone (AMH) is a glycoprotein with a fundamental role in male sex 52 
differentiation. In women, AMH plays a critical role in folliculogenesis, with circulating 53 
levels directly reflecting the number of developing preantral follicles and indirectly the 54 
number of primordial follicles in the ovaries (Iliodromiti et al., 2015). As such, AMH is now 55 
recognised as the best available biomarker of both the functional and true ovarian reserve 56 
(Dewailly et al., 2014). Accurate quantitative assessment of the ovarian reserve by AMH 57 
(Anderson et al., 2015) has enabled prediction of reproductive lifespan, tailoring of fertility 58 
preservation and optimisation of assisted conception outcomes (Dewailly et al., 2014; Nyboe 59 
Andersen et al., 2016).  The recent development of a fully automated Elecsys®  AMH 60 
immunoassay (Gassner and Jung 2014) with enhanced sensitivity, specificity and 61 
reproducibility, has widened its clinical utility and enabled assessment of women with limited 62 
ovarian function. 63 
Women with advanced chronic kidney disease (CKD) often have disturbances in the 64 
menstrual cycle and amenorrhea is common by the time the patient reaches end stage renal 65 
disease (ESRD) (Zingraff et al., 1982). The menstrual cycle typically remains irregular even 66 
after the initiation of maintenance dialysis. Consistent with this, pregnancy is extremely 67 
uncommon as one progresses from CKD stage 3 to dialysis (Zingraff et al., 1982). 68 
Conversely, fertility is frequently restored within a few months after successful kidney 69 
transplantation (Levidiotis et al., 2009). To date we are only aware of a single small study 70 
(n=60) assessing AMH in patients with renal failure(Sikora-Grabka et al., 2016). This study 71 
utilised a manual AMH ELISA, which was limited by complement interference, 72 
irreproducible results and limited sensitivity (Iliodromiti et al., 2015).  73 
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The aim of this study was to measure serum AMH concentrations in predialysis, dialysis and 74 
kidney transplant women of childbearing age; explore potential factors affecting AMH and 75 
compare AMH levels with age-matched healthy controls. 76 
  77 
Materials and methods 78 
Design and Participants 79 
This was a single-centre cohort study of all women aged 18-40 years attending renal services 80 
between August 1, 2015 and March 31, 2016 in our catchment area (serving a population of 81 
approximately 1.5 million). Potential participants were identified from the electronic patient 82 
record used in our centre and by screening clinic lists. A letter was sent to all eligible patients 83 
to make them aware of the research, which included an opt in or opt out reply slip where they 84 
could suggest a way for the research staff to contact them to discuss the study further. If they 85 
opted in, they were contacted by a member of the research team to discuss the details of the 86 
study and organise a study visit. The protocol of the study was approved by the Research 87 
Ethics Committee (REC reference: 15/NS/0040) on 20th May 2015. The study was conducted 88 
in accordance with the Declaration of Helsinki, and written informed consent was obtained 89 
from all participants. 90 
We measured serum AMH levels in three distinct groups of patients; women with CKD 91 
stages 3-5, women on haemodialysis (HD), and kidney transplant recipients. We excluded 92 
individuals with active or previous cancer (breast, ovarian, lymphoma, pelvic radiotherapy), 93 
ovarian surgery, current use of alkylating agent-based protocols, severe active illness and 94 
patients with inability to provide informed consent. 95 
AMH levels from a multicentre study using the same assay in 600 age-matched healthy 96 
women with regular menstrual cycles, not on contraception were used as the reference group 97 
(Anckaert et al., 2016).  98 
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 99 
Baseline data 100 
Demographics, aetiology of renal failure, duration of renal replacement therapy (RRT), actual 101 
day of the menstrual cycle during the examination, gynaecological history [including 102 
menstrual characteristics, number of pregnancies or miscarriages, history of polycystic ovary 103 
syndrome (PCOS), family history of premature menopause], and medications potentially (but 104 
not definitively) related to AMH concentrations (contraceptives (Bentzen et al., 2012; Deb et 105 
al., 2012), prednisolone (Ubaldi et al., 2002) and cyclophosphamide (Clowse et al., 2011)) 106 
were recorded. 107 
In addition to AMH, we measured a number of other hormones regulating the ovarian 108 
function, including follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, 109 
oestradiol and progesterone. Also, serum creatinine, C-reactive protein (CRP), and thyroid 110 
hormones blood concentrations were analysed based on literature showing potential 111 
associations with AMH (Yarde et al., 2014; Polyzos et al., 2015; Weghofer et al., 2016). 112 
Menstrual cycles were defined as regular when menstrual flow occurred every 21 to 35 days, 113 
irregular when menstrual flow occurred less than 21 days or more than 35 days apart, and 114 
amenorrhoea was defined as the abnormal absence of menstruation for 90 days or more in 115 
accordance with the NICE guideline (NICE 2014). The Chronic Kidney Disease 116 
Epidemiology Collaboration (CKD-EPI) equation was used for calculation of estimated 117 
glomerular filtration rate (eGFR) (Levey et al., 2009). 118 
 119 
Study procedures 120 
The blood samples were collected on a random day during the menstrual cycle and then 121 
anonymised and centrifuged. In the women on HD, blood samples were obtained before a HD 122 
session.  123 
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For measurement of AMH, 3mL serum aliquots for each patient were stored at -80oC. AMH 124 
was measured on first thaw of stored samples using an automated method on a clinically 125 
validated platform (e411, Roche Diagnostics, Burgess Hill, UK) (Gassner and Jung 2014). 126 
The assay was calibrated and quality controlled using the manufacturer’s reagents. Detection 127 
limit was 0.01ng/mL and the coefficient of variation between runs for two levels of control 128 
ran at <8%. All AMH samples (including controls) were measured in the same laboratory by 129 
the same laboratory-developed test methods in a single run, and all values can therefore be 130 
compared uniformly. 131 
All other biochemical parameters were measured using standard assays, in a National Health 132 
Service clinical biochemistry department. 133 
 134 
Statistical analysis 135 
We examined differences in demographic, clinical factors, and biochemical parameters 136 
stratified by renal failure group. Continuous variables were expressed with means and 137 
standard deviations (SD) or medians and interquartile ranges (for non-parametric data), and 138 
analysed using parametric and non-parametric tests as appropriate. Categorical variables were 139 
reported as frequencies and percentages and proportions compared by chi-squared or Fisher’s 140 
exact tests. 141 
For all comparisons, values of AMH were log transformed to normalise their distribution and 142 
were analysed as continuous variables.  143 
One-way ANOVA was performed in the transformed data to examine the percentage change 144 
in AMH between renal failure groups. Means (and SD) obtained from the logged values were 145 
exponentiated (back transformed) and are therefore the geometric means, which were derived 146 
after subtraction of the constant. 147 
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Correlation analyses were performed to assess the relationship between log transformed 148 
AMH and each predictor variable. Variables tested were age, weight, alcohol and smoking 149 
history, eGFR, renal failure group, cause of established renal failure (ERF), biochemical 150 
parameters (reproductive hormones, thyroid hormones and CRP), day of menstrual cycle, 151 
presence or not of menstrual periods, and medications potentially related to follicular growth 152 
(contraceptives, steroids, cyclophosphamide). Factors with p value <0.10 in correlation 153 
analyses were tested in linear regression models with log transformed AMH as the outcome 154 
variable. Coefficients obtained from linear regression models of the logged values were 155 
exponentiated (back transformed) and are therefore ratios of geometric means per 156 
unit/category change of the exposure and should be interpreted as proportional change per 157 
exposure with a null value of 1.  158 
Mean log transformed AMH levels of young women with renal failure were compared with 159 
age-matched healthy references using a two-sample z-test. Z-test was calculated for all 160 
patients and in subgroups stratified by age (≤25, 26-30, 31-35, and ≥36 years) and by renal 161 
failure group (CKD stages 3-5, HD, and transplant).  162 
The study was designed to enroll 75 participants (25 in each renal failure group), which 163 
would be sufficient to detect a significant difference between the healthy controls and women 164 
with renal failure assuming the difference in AMH between a healthy and renal failure 165 
woman is 0.4ng/mL and SD in each group is 0.7ng/mL, providing power of 80% and 166 
probability of type 1 error of 5%(Morel et al., 2013). 167 
For all analyses, a p value <0.05 was considered significant. The IBM SPSS Statistics 168 
Package (version 21.0; SPSS, Inc., Armonk, NY) was used for all analyses. 169 
 170 
Results 171 
Study population 172 
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We measured AMH levels in 77 women of childbearing age who were attending the renal 173 
services and fulfilled the study entry criteria. Twenty-six had CKD stages 3-5, 26 were on 174 
HD, and 25 had a kidney transplant (Table 1). 175 
Mean age of the enrolled participants was 32.9 (SD 5.4) years, 38 (49.3%) had regular 176 
menstrual periods, and approximately a third were on hormonal contraception. More than half 177 
had previous successful pregnancies and 18 (23.4%) had at least one miscarriage in the past. 178 
Six women (7.8%) had a history of PCOS. No differences of clinical importance were 179 
identified between the three groups (Table 1). 180 
 181 
Biochemical parameters 182 
Median AMH was higher in HD patients (2.9, IQR 1.1-5.2ng/mL) compared with CKD 183 
stages 3-5 patients (1.6, IQR 0.7-2.2ng/mL) and transplant patients (1.5, IQR 1.0-4.2ng/mL) 184 
(Table 2). By comparing the logged AMH values by ANOVA, there was significant 185 
difference in AMH levels between renal failure groups [F(2, 74)=3.686, p=0.03]. Tukey post 186 
hoc analysis revealed that AMH was significantly higher in HD patients (p=0.02) compared 187 
with CKD stages 3-5 patients. There was no difference between HD and transplant patients or 188 
between CKD and transplant patients. With regard to the rest of the biochemical parameters, 189 
there were no differences of note between the three groups, other than thyroid stimulating 190 
hormone (TSH) being marginally higher in the CKD group (although still within the ‘normal’ 191 
range) and the transplant patients having better renal function than those with CKD as 192 
expected. 193 
From all variables tested, age and renal failure group were associated with AMH on 194 
regression analysis (Table 3). When multiple linear regression analysis was performed, there 195 
was an average 4% (95%CI 0.02 to 0.06, p<0.001) decrease in AMH level per year increase 196 
in age when accounting for the renal failure group (Table 3). When compared with women 197 
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≤25 years, women older than 36 years had 39% (95%CI 0.08 to 0.62, p=0.04) lower AMH 198 
levels (Table 3). Patients on HD had higher AMH levels by 53% (95%CI 0.20 to 0.98, 199 
p=0.002) compared with CKD patients, following adjustment for age. No differences were 200 
found between the other renal failure groups. The multiple regression model fit was R-201 
squared=0.24 (Table 3). There was no difference in AMH levels between women with 202 
menstrual periods vs amenorrhoeic (1.7, IQR 0.8-3.9ng/mL vs 1.5, IQR 1.0-3.0ng/mL, 203 
respectively), previously treated with cyclophosphamide vs non-treated (1.5, IQR 0.4-204 
1.5ng/mL vs 1.7, IQR 0.9-3.9ng/mL, respectively), and women on hormonal contraception vs 205 
not (1.6, IQR 1.1-3.8ng/mL vs 1.7, IQR 0.8-3.4ng/mL, respectively).  206 
Women with renal failure had 43% lower AMH levels than healthy women (1.7, IQR 0.9-207 
3.8ng/mL vs 3.0, IQR 1.9-5.0ng/mL, p<0.001) (Figure 1). In subgroup analysis, AMH was 208 
lower in all age groups in women with renal failure, apart from those aged 26-30 years 209 
(≤25yr 1.7 vs 4.0ng/mL, p<0.04; 26-30yr 3.7 vs 3.2ng/mL, not significant; 31-35yr 2.1 vs 210 
2.6ng/mL, p=0.004; ≥36yr 1.0 vs 1.7ng/mL, not significant). When stratified by renal failure 211 
group, in comparison with healthy age-matched women controls, AMH was lower in women 212 
with CKD stages 3-5 (1.6 vs 3.0ng/mL, p<0.001) and women with a kidney transplant (1.5 vs 213 
3.0ng/mL, p<0.001) but not in women on HD (2.9 vs 3.0) (Figure 2). 214 
 215 
Discussion 216 
The data suggest that women of childbearing age with CKD stages 3-5 or a kidney transplant 217 
have lower AMH compared with age-matched women without kidney disease and this may 218 
contribute to the low fertility rate in this population. Notably, women on haemodialysis had 219 
similar AMH levels compared with age-matched controls and this may reflect an intrinsic 220 
dysregulation of the granulosa cells leading to higher AMH production or alternatively AMH 221 
accumulation in ERF requiring dialysis. In women with renal disease, increasing age was 222 
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associated with a reduction in AMH concentrations similar to that observed in the general 223 
population. Although pregnancy is extremely uncommon in this patient population, AMH 224 
may have a role as a marker of ovarian health in non-dialysis female renal patients pursuing 225 
pregnancy. In haemodialysis patients AMH levels seem to be inappropriately high therefore, 226 
patients in this group should be excluded from conclusions drawn about the relationship 227 
between AMH and ovarian reserve.  228 
To date, AMH has been developed with a wide array of clinical applications (Nelson 2013; 229 
Dewailly et al., 2014). These include prediction of the ovarian response to stimulation with 230 
exogenous gonadotrophins for in-vitro fertilisation, the duration of the reproductive lifespan 231 
and diagnosis of premature ovarian insufficiency, disorders of sex development and PCOS 232 
(Seifer et al., 2002; Stubbs et al., 2005; Josso et al., 2012; Iliodromiti et al., 2013; Rey et al., 233 
2013; Tehrani et al., 2013; La Marca and Sunkara 2014). AMH has also been used for the 234 
assessment of gonadotoxicity of cancer therapy, monitoring of granulosa cell tumors to detect 235 
residual or recurrent disease, and assessing the loss of the ovarian tissue secondary to ovarian 236 
surgery (La Marca and Volpe 2007; Geerts et al., 2009; Anderson and Wallace 2013). 237 
Women with renal failure and childbearing potential are a diverse group of patients with 238 
complex pathologies where AMH may provide valuable insight, especially to those 239 
considering future pregnancy.  240 
About 3% of women of childbearing age are affected by renal disease (Williams and Davison 241 
2008). However, the incidence of pregnancy in women with CKD stages 3-5 is difficult to 242 
determine as it is not routine practice to measure kidney function in pregnant women in the 243 
United Kingdom, unless there is some other indication. Furthermore, kidney function is 244 
difficult to interpret during pregnancy as GFR increases. The frequency of conception among 245 
women of childbearing age undergoing RRT ranges from 0.3 to 1.5% per year (Holley et al., 246 
1997). For transplant patients the unadjusted pregnancy rate is 33-45 per 1000 women (Gill et 247 
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al., 2009; Stoumpos et al., 2016) compared with more than 100 per 1000 women in the 248 
general population. 249 
Circulating AMH concentrations reflect the functional ovarian reserve and indirectly the 250 
number of residual primordial follicles within the ovary. As a consequence of this intimate 251 
relationship with the ovarian reserve, a decline in AMH may indicate both physiological and 252 
premature aging of the gonads (Kalaiselvi et al., 2012; Younis 2012). Applicable to the 253 
population with renal failure, in women with moderate to severe CKD (stages 3-5), the risk of 254 
complications to mother and fetus with pregnancy is high enough that some advocate against 255 
pregnancy or to postpone until they receive a kidney transplant. Similarly, female kidney 256 
transplant recipients are traditionally counselled to wait one to two years after transplantation 257 
before conceiving (McKay and Josephson 2008). This postponement frequently leads to 258 
women with renal disease attempting to have children during a period where female fertility 259 
is already in decline due to ageing. Furthermore, menopause in women with renal failure 260 
occurs 4.5 years earlier than in healthy women (Weisinger and Bellorin-Font 2004) leaving 261 
them with fewer potential childbearing years. Nonetheless, not all cases are clear-cut and 262 
there is a number of women with either advanced renal disease or a kidney transplant in 263 
whom assessment of AMH may be useful to guide pregnancy planning. For example, a young 264 
woman with normal AMH values would potentially have more time to deal with any 265 
underlying medical issues. In contrast, women with a borderline or low AMH, indicative of a 266 
diminished ovarian reserve, may be counselled that fertility preservation may be 267 
advantageous. 268 
Women on HD were found to have higher AMH concentrations compared with the other two 269 
renal failure groups and this was an unexpected finding. Impaired glomerular filtration could 270 
be a potential mechanism although AMH has a molecular weight of 140kD, which is too 271 
large to cross the basement membrane of the glomerular capillaries. On the other hand, AMH 272 
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is of similar size to other molecules perceived to be uraemic ‘toxins’ (Duranton et al., 2012) 273 
(i.e. fibrinogen, a2-macroglobulin) and although their concentrations are not directly 274 
associated with glomerular function they are increased in dialysis, so accumulation of AMH 275 
in dialysis is plausible. Uraemia is known to interfere with the metabolism and regulation of a 276 
number of endogenous hormones; however, the direct impact of uraemia in ovarian follicles 277 
and AMH levels is not clear. We hypothesise that high AMH levels during dialysis are 278 
probably related to the follicular arrest during the selection process of the dominant follicle, 279 
through a negative interaction between AMH and FSH (Grossman et al., 2008). If so, AMH 280 
significantly decreases FSH-induced oestradiol production, which leads to disruption of 281 
normal antral follicular development and maturation, similarly to what is happening in 282 
women with PCOS (Agarwal et al., 1996). In accordance with this, oestradiol levels were 283 
lower in women on HD compared with the other two renal failure groups, although the 284 
difference was not significant. In a study of 186 young healthy Danish women (Hagen et al., 285 
2012) that were followed until they conceived or for six menstrual cycles, the fecundability 286 
ratio (FR) (i.e., the monthly probability of conceiving) in women with low AMH levels was 287 
similar to women with medium AMH levels (FR 0.81; 95% CI 0.44–1.40) but women with 288 
high AMH levels had reduced FR (FR 0.62; 95% CI 0.39–0.99). This supports our findings, 289 
where high AMH levels may represent women with conditions of anovulation. In a recently 290 
published study (Sikora-Grabka et al., 2016), women on HD had similar AMH concentrations 291 
with healthy women and this is similar to our findings. However, when women on HD were 292 
stratified into those with regular menstrual cycles vs not, the regularly menstruating women 293 
on HD had significantly lower serum AMH concentration compared with the healthy 294 
controls. In our study there was no difference in AMH concentrations between women on HD 295 
with regular, irregular periods or amenorrhoea; however, the numbers were very small (n=11, 296 
n=8 and n=7, respectively). In the same study, AMH concentrations were found to gradually 297 
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decrease from pre- to 6 months post-transplantation and this may reflect the transition from 298 
abnormally high AMH concentrations during dialysis to lower ‘normal’ concentrations post-299 
transplantation. 300 
Our study has a number of strengths including the use of a cohort of young, well-phenotyped 301 
women with renal failure, distinct clinical categorisation of disease progression and that we 302 
could compare them with a large cohort of age-matched healthy controls. We performed 303 
extensive biochemical characterisation, including use of a robust automated AMH assay. We 304 
do however, acknowledge some limitations: information on menstrual cycle characteristics 305 
were not easy to ascertain in all cases, especially in women with scanty menstrual periods; 306 
however, AMH has been shown to be stable throughout the menstrual cycle and in women 307 
with irregular cycles random sampling is inevitable. We had limited power to assess the 308 
effects of cyclophosphamide or the combined oral contraceptive pill, but overall AMH was 309 
reduced in keeping with previous larger studies. In women with renal failure other markers of 310 
ovarian reserve, such as antral follicle count (AFC) which is an ultrasound biomarker of 311 
follicle number may be a better predictor of oocyte yield than AMH. We were unable to 312 
perform transvaginal ultrasound examination and AFC measurement to provide additional 313 
assessment of the ovarian reserve; however, AFC is not routinely available and is known to 314 
exhibit substantial intra- and interobserver variability. Lastly, we accept that no causal 315 
inferences on the effect of renal failure on AMH levels can be made, with prospective 316 
longitudinal studies best placed to address this. 317 
We demonstrate that in women of reproductive age with CKD stages 3-5 or a renal 318 
transplant, AMH exhibits a similar age-related decline but age-specific values are lower than 319 
equivalent healthy controls. For women on HD circulating AMH concentrations are higher, 320 
suggesting a disruption of folliculogenesis or impaired clearance. AMH evaluation may be a 321 
useful biochemical test in estimating the reproductive lifespan in women with renal disease 322 
14 
 
not treated with dialysis, pursuing preconception counselling. However, it is important to 323 
note that AMH is only a marker of ovarian reserve and should be used as an adjuvant tool. 324 
Conception can be achieved with low AMH levels therefore, one should be careful about the 325 
interpretation of AMH as a prognostic marker for conception success. Further research is 326 
warranted to investigate the direct impact of uraemia on ovarian follicles and AMH 327 
production. 328 
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Figure 1. Log AMH levels in young women with CKD (n=77) compared with AMH levels in a cohort of 600 age-matched healthy women 487 
(p<0.001, two-sample z-test). Data are log-transformed. 488 
AMH, anti-Müllerian hormone; CKD, chronic kidney disease. 489 
 490 
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Figure 2. Age-related distribution of serum log AMH levels in women of reproductive age with CKD stages 3-5 (n=26), on HD (n=26), kidney 491 
transplant recipients (n=25) and healthy controls (n=600). Data are log-transformed.  492 
AMH, anti-Müllerian hormone; CKD, chronic kidney disease; HD, haemodialysis. 493 
494 
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Table 1. Baseline characteristics stratified by renal failure group 
 All patients (n=77) CKD (n=26) HD (n=26) Transplant (n=25) p-valuea 
Age (years), mean (SD) 32.9 (5.4) 33.4 (5.4) 34.0 (4.9) 31.2 (5.8) NS 
Weight (kg), mean (SD) 68.1 (17.8) 71.2 (18.8) 66.8 (15.3) 66.1 (19.4) NS 
Ethnic origin 
Caucasian, n (%) 
Asian, n (%) 
 
66 (85.7) 
11 (14.3) 
 
20 (76.9) 
6 (23.1) 
 
26 (100.0) 
0 (0.0) 
 
20 (80.0) 
5 (20.0) 
 
0.04 
Smokingb, n (%) 25 (32.5) 7 (26.9) 12 (46.2) 6 (24.0) NS 
Alcoholc, n (%) 40 (51.9) 17 (65.4) 11 (42.3) 12 (48.0) NS 
Cause of ERF 
Glomerulonephritis, n (%) 
Congenital renal dysplasia/reflux, n (%) 
Diabetes, n (%) 
Otherd, n (%) 
 
31 (40.3) 
14 (18.2) 
12 (15.6) 
20 (26.0) 
 
10 (38.5) 
3 (11.5) 
6 (23.1) 
7 (26.9) 
 
9 (34.6) 
5 (19.2) 
5 (19.2) 
7 (26.9) 
 
12 (48.0) 
6 (24.0) 
1 (4.0) 
6 (24.0) 
 
NS 
 
 
Years on RRT, median (IQR) 4.3 (1.6, 11.3)  2.8 (0.6, 7.5) 8.7 (3.1, 12.0) 0.03 
Menstrual periods 
Amenorrhoea, n (%) 
Regular, n (%) 
Irregular, n (%) 
 
15 (19.5) 
38 (49.4) 
24 (31.2) 
 
5 (19.2) 
12 (46.2) 
9 (34.6) 
 
7 (26.9) 
11 (42.3) 
8 (30.8) 
 
3 (12.0) 
15 (60.0) 
7 (28.0) 
 
NS 
 
 
Previous pregnancies, n (%) 46 (59.7) 15 (57.7) 17 (65.4) 14 (56.0) NS 
Previous miscarriages, n (%) 18 (23.4) 8 (30.8) 5 (19.2) 5 (20.0) NS 
Polycystic ovary syndrome, n (%) 6 (7.8) 2 (7.7) 1 (3.8) 3 (12.0) NS 
Family history of premature menopausee, n (%) 3 (5.5) 3 (16.7) 0 (0.0) 0 (0.0) 0.04 
Medications related to follicular growth 
Hormonal contraception, n (%) 
Steroids, n (%) 
Previous cyclophosphamide, n (%) 
 
29 (37.7) 
37 (48.1) 
5 (6.5) 
 
12 (46.2) 
5 (19.2) 
2 (7.7) 
 
8 (30.8) 
8 (30.8) 
1 (3.8) 
 
9 (36.0) 
24 (96.0) 
2 (8.0) 
 
NS 
<0.001 
NS 
21 
 
a ANOVA or chi-squared test or Fisher’s exact test or Mann-Whitney U test where appropriate 
b Current or previous vs never 
c Occasionally (<14units/week) vs never 
d Polycystic kidney disease (n=6), unknown aetiology (n=6), haemolytic uremic syndrome (n=2), post-acute kidney injury (n=2), malignant 
hypertension (n=1), tubulointerstitial nephritis (n=1), amyloidosis (n=1), nephronophthisis (n=1) 
e Excludes 22 patients with missing values 
CKD, chronic kidney disease; HD, haemodialysis; SD, standard deviation; NS, not statistically significant; ERF, established renal failure; RRT, 
renal replacement therapy; IQR, interquartile range. 
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Table 2. Biochemical parameters stratified by renal failure group 
 All patients (n=77) CKD (n=26) HD (n=26) Transplant (n=25) p-valuea 
eGFRb, mL/min/1.73m2; mean (SD) 
<45b, n (%) 
≥45, n (%) 
50.8 (27.6) 
26 (51.0) 
25 (49.0) 
34.4 (15.3) 
19 (73.1) 
7 (26.9) 
 67.2 (27.7) 
7 (28.0) 
18 (72.0) 
<0.001 
0.005 
Day of menstrual cyclec, median (IQR) 12 (6-22) 16 (5-24) 12 (4-22) 12 (9-17) 0.77 
Anti-Müllerian hormone, ng/mL; median (IQR) 1.7 (0.9, 3.8) 1.6 (0.7, 2.2) 2.9 (1.1, 5.2) 1.5 (1.0, 4.2) 0.03d 
Anti-Müllerian hormone, ng/mL; geometric mean 
(SD)e 
1.9 (0.7) 1.4 (0.5) 2.6 (0.8) 1.8 (0.8)  
Follicle-stimulating hormone, IU/L; median (IQR) 4.1 (2.5, 6.0) 5.1 (3.7, 6.0) 3.8 (2.6, 5.6) 3.0 (2.5, 6.3) 0.37 
Luteinising hormone, IU/L; median (IQR) 6.5 (3.8, 10.0) 6.8 (3.8, 8.3) 5.0 (3.6, 11.5) 5.6 (3.8, 12.4) 1.00 
Prolactin, mIU/L; median (IQR) 360 (247, 563) 306 (243, 469) 444 (345, 652) 315 (206, 544) 0.08 
Oestradiol, pmol/L; median (IQR) 242 (102, 395) 226 (113, 326) 130 (82, 317) 320 (132, 585) 0.12 
Progesterone, nmol/L; median (IQR) 1.3 (1.0, 4.7) 1.1 (1.0, 4.8) 1.6 (1.2, 4.2) 1.0 (1.0, 3.2) 0.45 
Thyroid stimulating hormone, mIU/L; median 
(IQR) 
1.5 (0.9, 2.1) 1.8 (1.4, 2.4) 1.3 (0.9, 1.7) 1.1 (0.7, 2.0) 0.03 
Free thyroxine, pmol/L; median (IQR) 13.2 (12.4, 14.9) 12.9 (12.3, 14.6) 13.2 (12.4, 14.1) 14.0 (12.7, 15.5) 0.38 
C-reactive protein, mg/L; median (IQR) 2.5 (1.0, 6.3) 2.0 (1.0, 5.0) 3.5 (1.0, 9.8) 2.0 (1.0, 5.0) 0.37 
a T-test or chi-squared test or Kruskal-Wallis test or ANOVA where appropriate 
b Excludes patients on dialysis 
c Excludes 15 women with amenorrhoea and 8 women with menstrual cycles >35 days 
d P-value was obtained by comparing logged values 
e Geometric means were derived from logged AMH values after back transformation 
CKD, chronic kidney disease; HD, haemodialysis; eGFR, estimated glomerular filtration rate; SD, standard deviation; IQR, interquartile range. 
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Table 3. Covariates associated with AMH levels 
Covariate Simple linear regression Multiple linear regression 
Ratio of geometric means 
(Bootstrap 95%CI) 
p-
value 
R-
square 
Ratio of geometric means 
(Bootstrap 95%CI) 
p-
value 
R-
square 
Age (each additional 
year) 
-0.04 (-0.06 to -0.02) 0.001 0.15 -0.04 (-0.06 to -0.02) <0.001 0.24 
Renal failure group 
     CKD (reference) 
     HD 
     Transplant 
 
1.0 
0.49 (0.16 to 1.00) 
0.16 (-0.13 to 0.53) 
 
- 
0.009 
0.31 
0.09 
 
 
1.0 
0.53 (0.20 to 0.98) 
0.06 (-0.18 to 0.36) 
 
- 
0.002 
0.70 
Age group 
     ≤25 (reference) 
     26-30 
     31-35 
     ≥36 
 
1.0 
0.04 (-0.34 to 0.60) 
-0.20 (-0.49 to 0.22) 
-0.39 (-0.62 to -0.08) 
 
- 
0.88 
0.36 
0.04 
0.16  
AMH, anti-Müllerian hormone; CI, confidence interval; CKD, chronic kidney disease; HD, haemodialysis. 
 
